Display options
Cite
Langston AA, Quest TE, Abernethy ER, et al. Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer. Oncologist. 2020;25(10):e1586-e1588doi: 10.1634/theoncologist.2020-0442.
Langston, A. A., Quest, T. E., Abernethy, E. R., Campbell, G. P., Owonikoko, T. K., & Pentz, R. D. (2020). Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer. The oncologist, 25(10), e1586-e1588. https://doi.org/10.1634/theoncologist.2020-0442
Langston, Amelia A, et al. "Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer." The oncologist vol. 25,10 (2020): e1586-e1588. doi: https://doi.org/10.1634/theoncologist.2020-0442
Langston AA, Quest TE, Abernethy ER, Campbell GP, Owonikoko TK, Pentz RD. Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer. Oncologist. 2020 Oct;25(10):e1586-e1588. doi: 10.1634/theoncologist.2020-0442. Epub 2020 Aug 27. PMID: 32744382; PMCID: PMC7436378.
Copy Download .nbib Format: NLM
Share it on

Oncologist. 2020 Oct;25(10):e1586-e1588. doi: 10.1634/theoncologist.2020-0442. Epub 2020 Aug 27.

Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer.

The oncologist

Amelia A Langston, Tammie E Quest, Eli Rowe Abernethy, Gavin Paul Campbell, Taofeek K Owonikoko, Rebecca D Pentz

Affiliations

  1. Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  2. Emory University School of Medicine, Atlanta, Georgia, USA.

PMID: 32744382 PMCID: PMC7436378 DOI: 10.1634/theoncologist.2020-0442

Abstract

The oncology community is concerned that patients with cancer will be unfairly classified in pandemic allocation guidance. Past guidance either excluded patients with metastatic cancer from consideration or categorized them as having a survival of less than 1 year. Given recent improvements in treatments, we recommend that the prognosis of an individual patient with cancer be determined with input from a cancer specialist or, if this is impractical, that the presence of active metastatic solid cancer or relapsed hematologic malignancy is graded as a major comorbidity, with a likelihood that survival will be less than 5 years; severe limitation in physical functioning (3 or 4 on the Eastern Cooperative Oncology Group performance status) would define a patient with advanced cancer as having a severe comorbidity, with a likelihood of less than 1 year of survival. Cancer may be the "Emperor of all Maladies," but it is no longer a certain death sentence.

© 2020 AlphaMed Press.

References

  1. Oncologist. 2020 Jun;25(6):e936-e945 - PubMed
  2. JAMA Oncol. 2015 Sep;1(6):778-84 - PubMed
  3. J Clin Oncol. 2020 Jul 1;38(19):2201-2205 - PubMed
  4. N Engl J Med. 2020 May 21;382(21):2049-2055 - PubMed
  5. Lancet Haematol. 2015 May;2(5):e186-93 - PubMed
  6. J Natl Cancer Inst. 2017 Sep 1;109(9): - PubMed
  7. J Oncol Pract. 2014 Sep;10(5):e335-41 - PubMed

MeSH terms

Publication Types